Fig. 2: Summary of anticholinergic AEs. | Schizophrenia

Fig. 2: Summary of anticholinergic AEs.

From: Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia

Fig. 2

a Time to onset and b duration of peripheral anticholinergic AEs. Duration was calculated as (AE end date−AE start date) +1, except for two instances of constipation that were ongoing at the end of the trial, in which case duration was imputed using end of study date instead of AE end date. AE adverse event.

Back to article page